Methyl-pamoat | 63170-41-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: Methyl-pamoat
• 英文别名: methyl pamoate；Methyl 3-hydroxy-4-[(2-hydroxy-3-methoxycarbonylnaphthalen-1-yl)methyl]naphthalene-2-carboxylate
• CAS: 63170-41-2
• 化学式: C₂₅H₂₀O₆
• 分子量: 416.43
• InChiKey: BHFXKNGELGUNMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  93.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Methyl-pamoat 在 lithium aluminium tetrahydride 、 三溴化磷 、 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙酸乙酯 、 丙酮 为溶剂， 反应 210.0h， 生成 N,N,N-bis(2-picolyl)-(2,2'-[1,2-ethanediylbis(oxy)]-1,1'-dinaphthylmethane-3,3'-methyl) amine
  参考文献：
  名称：

  双核铜（II）配合物1：磷酸酶样活性中新配合物的合成，表征和评估

  摘要：

  摘要合成了一种新的双核型铜双价铜配合物，并通过X射线晶体学对其进行了表征。检查该络合物作为双（对硝基苯基）磷酸酯水解中的催化剂。在各种pH下研究了其催化性能，并将其与单核Cu（II）配合物进行了比较。在pH 5.38时，双核Cu（II）络合物显示出具有11 TON和24％转化率的磷酸酶样活性，并且发现其活性比单核对应物高41倍。

  DOI：

  10.1016/j.ica.2012.04.019

文献信息

• [EN] A PROCESS FOR THE PREPARATION OF PYRVINIUM PAMOATE AND CRYSTALLINE FORMS THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION DE PAMOATE DE PYRVINIUM ET DE FORMES CRISTALLINES DE CELUI-CI
  申请人：URQUIMA SA

  公开号：WO2017178524A1

  公开（公告）日：2017-10-19

  The present invention relates to a process for the preparation of pyrvinium pamoate, which comprises reacting pyrvinium methyl sulphate salt of formula (II) with disodium pamoate of formula (III), in the presence of a base; to processes for the preparation of crystalline Form A and crystalline Form III of pyrvinium pamoate; as well as a process for the purification of crystalline Form III. It also relates to crystalline Forms A and III of pyrvinium pamoate and to pharmaceutical compositions containing them.

  本发明涉及一种用于制备吡替硫酸吡替硫盐的方法，包括在碱的存在下，将化学式（II）的吡替硫酸甲基硫酸盐与化学式（III）的二钠吡替硫酸盐反应；以及制备吡替硫酸吡替硫晶型A和晶型III的方法；以及一种用于净化晶型III的方法。本发明还涉及吡替硫酸吡替硫晶型A和晶型III，以及含有它们的药物组合物。
• A PROCESS FOR THE PREPARATION OF PYRVINIUM PAMOATE AND CRYSTALLINE FORMS THEREOF
  申请人：Urquima S.A.

  公开号：EP3231796A1

  公开（公告）日：2017-10-18

  The present invention relates to a process for the preparation of pyrvinium pamoate, which comprises reacting pyrvinium methyl sulphate salt of formula (II) with disodium pamoate of formula (III), in the presence of a base; to processes for the preparation of crystalline Form A and crystalline Form III of pyrvinium pamoate; as well as a process for the purification of crystalline Form III. It also relates to crystalline Forms A and III of pyrvinium pamoate and to pharmaceutical compositions containing them.

  本发明涉及一种制备吡维溴铵帕莫酸盐的方法，其包括在碱的存在下，将式（II）的吡维溴铵甲基硫酸盐与式（III）的双钠帕莫酸盐反应；以及制备吡维溴铵帕莫酸盐的结晶形式A和结晶形式III的方法。同时还涉及一种纯化结晶形式III的方法。本发明还涉及吡维溴铵帕莫酸盐的结晶形式A和结晶形式III，以及含有它们的制药组合物。
• Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical
  申请人：K.U. LEUVEN RESEARCH & DEVELOPMENT

  公开号：EP0998946A1

  公开（公告）日：2000-05-10

  The invention relates to a non porphyrin compound or a pharmaceutically acceptable salt thereof, suitable for in vitro, in vivo and/or ex vivo use as a diagnosticum and/or pharmaceutical, said compound comprising: a targeting agent for targeting a specific area, such as an organ and/or tissue, a labelling agent L for labelling the targeted area; said targeting agent being connected to the labelling agent L, wherein said targeting agent comprises one or more substituted and/or unsubstituted organic ring compounds.

  本发明涉及一种非卟啉化合物或其药学上可接受的盐，适用于体外、体内和/或体外诊断和/或制药，所述化合物包括 靶向剂，用于靶向特定区域，如器官和/或组织、 用于标记目标区域的标记剂 L；所述靶向剂与标记剂 L 连接、 其中，所述靶向剂包括一种或多种取代和/或未取代的有机环化合物。
• [EN] NON-PORPHYRIN COMPOUND FOR USE AS A DIAGNOSTICUM AND/OR PHARMACEUTICAL<br/>[FR] COMPOSE NON PORPHYRINE UTILISE A DES FINS DIAGNOSTIQUES ET/OU PHARMACEUTIQUES
  申请人：LEUVEN K U RES & DEV

  公开号：WO2000009169A1

  公开（公告）日：2000-02-24

  The invention relates to a non porphyrin compound or a pharmaceutically acceptable salt thereof, suitable for in vitro, in vivo and/or ex vivo use as a diagnosticum and/or pharmaceutical, said compound comprising: a targeting agent for targeting a specific area, such as an organ and/or tissue, a labelling agent L for labelling the targeted area; said targeting agent being connected to the labelling agent L, wherein said targeting agent comprises one or more substituted and/or unsubstituted organic ring compounds.